Although amino acid substitution is an effective strategy to reduce proteolytic degradation, modified GLP-1 analogs are still subject to rapid renal clearance, making it difficult to further prolong peptide circulation time
As we age, changes in our body chemistry and reduced blood flow can affect several important functions, including: Slower and less efficient mitochondrial activity Decline in memory, attention, and mental alertness Reduced cerebral blood flow Lower production of neurotransmitters Increased free radical damage to brain cells Methylene blue therapy may help counter some of these effects by improving mitochondrial efficiency, enhancing energy production in brain cells, increasing oxygen delivery, and reducing oxidative stress
The usual incidence of the condition is between 2 and 10 cases per 100,000 people in the United States
Seek providers who specifically list peptide therapy, metabolic health, or obesity medicine in their practice profile